Priorities and practicalities of prescribing diabetes medicines with cardiovascular and renal protective effects: an Australian perspective

Sarah A. Hitchen, Nick S.R. Lan, P. Gerry Fegan, Bu B. Yeap

Research output: Contribution to journalArticle

Abstract

Recent cardiovascular safety trials on sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists have demonstrated the significant cardiovascular and renal benefits of these medications. Diabetes organisations have revised their medication guidelines to include a focus on disease outcomes for cardiovascular disease, heart failure and renal disease. This article summarises latest evidence, guideline recommendations and current Australian Pharmaceutical Benefits Scheme requirements.

Original languageEnglish
Pages (from-to)1423-1429
Number of pages7
JournalInternal Medicine Journal
Volume50
Issue number11
DOIs
Publication statusPublished - Nov 2020

Fingerprint

Dive into the research topics of 'Priorities and practicalities of prescribing diabetes medicines with cardiovascular and renal protective effects: an Australian perspective'. Together they form a unique fingerprint.

Cite this